Longitudinal IgA and IgG Response, and ACE2 Binding Blockade, to Full-Length SARS-CoV-2 Spike Protein Variants in a Population of Black PLWH Vaccinated with ChAdOx1 nCoV-19
Authors:
- Muneerah SmithMSMuneerah Smith
- Gaurav KwatraGKGaurav Kwatra
- Alane IzuAIAlane Izu
- Andrew NelANAndrew Nel
- Clare CutlandCCClare Cutland
- Khatja AhmedKAKhatja Ahmed
- Vicky BaillieVBVicky Baillie
- Shaun BarnabasSBShaun Barnabas
- Qasim BhoratQBQasim Bhorat
- Carmen BrinerCBCarmen Briner
- Erica LazarusELErica Lazarus
- Keertan DhedaKDKeertan Dheda
Open Access
Abstract
Vaccines against SARS-CoV-2 have been pivotal in overcoming the COVID-19 pandemic yet understanding the subsequent outcomes and immunological effects remain crucial, especially for at-risk groups e.g., people living with human immunodeficiency virus (HIV) (PLWH). In this study we report the longitudinal IgA and IgG antibody titers, as well as antibody-mediated angiotensin converting enzyme 2 (ACE2) binding blockade, against the SARS-CoV-2 spike (S) proteins after 1 and 2 doses of the ChAdOx1 nCoV-19 vaccine in a population of Black PLWH. Here, we report that PLWH (N = 103) did not produce an anti-S IgA response after infection or vaccination, however, anti-S IgG was detected in response to vaccination and infection, with the highest level detected for infected vaccinated participants. The anti-IgG and ACE2 blockade assays revealed that both vaccination and infection resulted in IgG production, however, only vaccination resulted in a moderate increase in ACE2 binding blockade to the ancestral S protein. Vaccination with a previous infection results in the greatest anti-S IgG and ACE2 blockade for the ancestral S protein. In conclusion, PLWH produce an anti-S IgG response to the ChAdOx1 nCoV-19 vaccine and/or infection, and ChAdOx1 nCoV-19 vaccination with a previous infection produced more neutralizing antibodies than vaccination alone.Keywords
All Related Versions
Funding Information
- J.M.Bs NRF SARCHI (64760, 96838)
- South African Medical Research Council (64760, 96838)
This publication has 19 references indexed in Scilit:
- Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA VaccineNew England Journal of Medicine, 2021
- IgA dominates the early neutralizing antibody response to SARS-CoV-2Science Translational Medicine, 2021
- COVID-19 death in people with HIV: interpret cautiouslyThe Lancet HIV, 2021
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet, 2021
- Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South AfricamedRxiv, 2020
- Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responsesNature Medicine, 2020
- OptimalCutpoints: AnRPackage for Selecting Optimal Cutpoints in Diagnostic TestsJournal of Statistical Software, 2014
- Chemical Genomics and Proteomics2012
- Miniaturized, Microarray-Based Assays for Chemical Proteomic Studies of Protein Function2011
- Dysfunctional B-cell responses during HIV-1 infection: implication for influenza vaccination and highly active antiretroviral therapyThe Lancet Infectious Diseases, 2010